companies / solvetx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-17 json
| total_raised | 321,000,000321.0M | ○ |
|---|---|---|
| founded | null | |
| hq | San Diego, United States | |
| industry | unknown | |
| stage | series-b+ |
Solve Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for solid tumors. It serves patients with cancers driven by selectively expressed tumor antigens, with leads SLV-154 and SLV-324 in Phase 1 trials. Its CloakLink hydrophilic linker improves ADC stability and widens the therapeutic window.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-11-01 | series-d+ | 120,000,000120.0M | null | ○ |
nginx
| fact | status | src |
|---|---|---|
| Series D+, $120.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |